The China Commercial Insurance Innovative Drug List (CIIDL) is a government-led formulary that recommends high-value, high-cost innovative drugs for commercial insurance, with the aim of supplementing the National Reimbursement Drug List (NRDL), which provides more foundational coverage for necessary medicines.
The National Healthcare Security Administration (NHSA) engages clinical and negotiation experts to assess manufacturer submissions and establish a list of innovative drugs, with the aim that commercial insurance, such as City Commercial Insurance, will cover these recommended drugs.
In this infographic by CRA’s Bhavesh Patel and Harvey Feng, the authors explore the outcomes of the first CIIDL negotiations, the potential benefits of inclusion, and what is needed to drive successful implementation.
